Chronic pain in dogs from osteoarthritis, cancer, and neuropathic conditions requires multimodal management combining pharmaceuticals, physical therapy, and environmental modification for optimal long-term welfare.
Chronic pain management in dogs is a welfare priority because inadequately treated pain accumulates as sustained suffering over months or years. The stoicism dogs show in chronic pain contexts — continuing to attempt normal activities despite discomfort — creates conditions where owners underestimate pain severity and treatment urgency. Multimodal management that addresses pain through multiple mechanisms provides superior welfare outcomes compared to single-drug approaches, while allowing reduced doses of individual medications to minimize side effects. The development of monoclonal antibody analgesics represents a significant welfare advance by providing a well-tolerated long-term pain management option.